#United States #San Diego #Clinical Research #Inhibrx #DR5 Agonist

Inhibrx Biosciences to Present at Major Scientific Conferences

Inhibrx Biosciences, Inc. (Nasdaq: INBX), a biopharmaceutical firm specializing in innovative biological therapies, has announced exciting participation details for a series of important scientific events throughout November 2025. This initiative marks a significant step in sharing their pioneering research on therapeutic candidates aimed at revolutionizing oncology treatments.

Upcoming Conferences

Inhibrx is scheduled to present at three notable conferences this month:

1. 21st Annual Industry/Academia Precision Oncology Radmed Symposium

Date: November 5, 2025
Location: La Jolla, California
Presentation: "DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer, and Ewing's Sarcoma"
Presenters: Josep Garcia, PhD, and Katelyn Willis, PhD.
The presentation will focus on the clinical data surrounding the DR5 agonist, delving into its efficacy across various cancer types. This session aims to provide insights that could be instrumental in advancing treatment options for patients.

2. Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting

Dates: November 12-15, 2025
Location: Boca Raton, Florida
Presentation: "The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma - Results from the Randomized, Registrational, Phase 2 ChonDRAgon Study"
Lead Author: Robin L. Jones, MD.
This critical discussion will highlight groundbreaking results from the Phase 2 ChonDRAgon study, emphasizing the promising effects of ozekibart on conventional chondrosarcoma, a rare yet challenging cancer diagnosis.

3. Society for NeuroOncology (SNO) 2025 Annual Meeting

Dates: November 19-23, 2025
Location: Honolulu, Hawaii
Presentation: "The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ"
This session will present a poster discussing the anti-tumor activities of INBRX-109, positioning it as a vital subject of discussion for ongoing neuro-oncology treatment approaches.

Investing in Future Innovations

Inhibrx's presentations this November are more than just routine updates; they represent a commitment to leading-edge research and development in the biopharmaceutical landscape. By actively engaging in these conferences, Inhibrx aims to showcase their innovations and push the boundaries of current treatment modalities for cancers that have limited therapeutic options.

Corporate Background

Founded in January 2024, Inhibrx Biosciences operates as a wholly-owned subsidiary of Inhibrx, Inc., focusing on the development of a diverse pipeline of therapeutic candidates. Through rigorous scientific methodologies and proprietary engineering platforms, Inhibrx targets complex disease biology, significantly enhancing the prospects within the oncology segment.

The presentations mentioned will be available for review via a dedicated link on Inhibrx's investor relations page upon the commencement of each event. As the company continually strives to enhance its outreach and share knowledge, these sessions will be vital for stakeholders, investors, and the broader scientific community to understand more about their therapies’ networking and efficacy.

Conclusion

Inhibrx Biosciences stands at the forefront of biopharmaceutical innovation, ready to unveil data that could alter the landscape of cancer therapies. By partaking in these pivotal conferences, the company not only furthers its scientific dialogue but also solidifies its place within a community committed to advancing cancer treatment efficacy.

To know more about their upcoming presentations and innovations, visit Inhibrx's official website.